Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?

What happened: Xencor ($XNCR) scheduled an October 26 webcast to review Phase 1 data for its XmAb819 kidney cancer program and flagged plans for a registration-enabling study in 2027. Key numbers: 1-day share price return 1.53%, 7-day decline 7.35%, 90-day return 13.45%, year-to-date gain 55.50%. Why it matters: The article frames the gap to analyst targets as a question of whether the market's caution on losses and pipeline risk is justified, and notes the story could shift if TL1A competition erodes market share or late stage trials slip on timing and outcomes. Market: +1.5% today ($23.19), +55.4% YTD, 1.5x vol — as of 22:46 UTC

Xencor ($XNCR) scheduled an October 26 webcast to review Phase 1 data for its XmAb819 kidney cancer program and flagged plans for a registration-enabling study in 2027.

The article frames the gap to analyst targets as a question of whether the market's caution on losses and pipeline risk is justified, and notes the story could shift if TL1A competition erodes market share or late stage trials slip on timing and outcomes. Market: +1.5% today ($23.19), +55.4% YTD, 1.5x vol — as of 22:46 UTC